Mikhail Blagosklonny
Mikhail Blagosklonny | |
|---|---|
| Alma mater | First Pavlov State Medical University of St. Peterburg |
| Scientific career | |
| Fields | Anti-aging medicine, oncology |
| Institutions | |
Mikhail Blagosklonny was a scientist who studied cancer and aging. He died in October 2024. He was an adjunct faculty member at Roswell Park Comprehensive Cancer Center in Buffalo, New York.[1]
Career
[edit]Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[citation needed] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Comprehensive Cancer Center.[2]
Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[3] Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.[1]
Rapamycin and aging
[edit]Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[4] He advocates for rapamycin use in longevity research.[5]
Editorial activities
[edit]Blagosklonny is editor-in-chief of Aging,[6] Cell Cycle,[7] and Oncotarget.[8] In addition, he is associate editor of Cancer Biology & Therapy[9] and a member of the editorial board of Cell Death & Differentiation.[10]
The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,[11] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[12] in July 2015.[11] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.[13]
Health
[edit]Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.[14] He died in October 2024 at the age of 63.[15]
References
[edit]- ^ a b "About Mikhail Blagosklonny". Roswell Park Comprehensive Cancer Center. Retrieved May 14, 2021.
- ^ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute", Cancer Biology & Therapy, 8 (9): 753–752, May 2009, doi:10.4161/cbt.8.9.8899
- ^ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute". Cancer Biology & Therapy. 8 (9): 753–752. May 2009. doi:10.4161/cbt.8.9.8899.
- ^ Stipp, David (2011). "A New Path to Longevity". Scientific American. 306 (1): 32–39. Bibcode:2011SciAm.306f..32S. doi:10.1038/scientificamerican0112-32. PMID 22279832.
- ^ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Bloomberg.com. 12 February 2015. Retrieved November 20, 2016.
- ^ "Editorial Board". Aging. Archived from the original on 2009-01-25. Retrieved 2016-11-20.
- ^ "Editorial Board". Cell Cycle. Taylor & Francis. Retrieved 2016-11-20.
- ^ "Editorial Board". Oncotarget. Retrieved 2016-11-20.
- ^ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20.
- ^ "About the journal". Cell Death & Differentiation. Retrieved 2016-11-20.
- ^ a b Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. Archived from the original on 20 April 2016. Retrieved 2016-11-20.
- ^ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. Archived from the original on 2 December 2016. Retrieved 19 April 2016.
- ^ "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. 6 December 2016. Archived from the original on 24 December 2016. Retrieved 17 January 2017.
- ^ "My battle with cancer". 26 October 2023.
- ^ "Passing of Dr. Misha Blagoskonny". Rapamycin News. Retrieved 2024-10-09.
| International | |
|---|---|
| National | |
| Academics | |
